Wang Rulan, Wang Ting, Zhou Qinghua
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Front Oncol. 2022 Aug 25;12:963094. doi: 10.3389/fonc.2022.963094. eCollection 2022.
Most parotid metastases have been reported to come from the head and neck; however, cases metastasized from the lung are extremely rare. Missed diagnoses and misdiagnoses occurred quite a few times. Thus, accurately identifying the clinical features of parotid metastasis of lung cancer is important. However, current studies about this issue are mostly case reports, and little is known about the detailed and systematic aspects. We reported three cases of parotid metastases from lung cancer and then systematically searched similar cases through "Pub-Med" and "Web of Science". Finally, twenty-three patients were included in the study. Eighty-three percent of which were males, and 19 patients were over 50 years old. In all cases with smoking history mentioned, 93% were smokers. The predominant pathological type was small cell lung cancer (SCLC, 13 patients, 56%). Seventeen combined with other site metastasis, while more than half of which were brain metastases. The survival time ranged from 3months-17years, and as for SCLCs, it was only 3months-40months. It can be concluded that clinical features, such as sex, age, smoking history, pathological types, and metastasis patterns, could provide valuable evidence for diagnosis. The lung seems to be the most common primary site of parotid metastases except for head and neck tumors. The two circumstances, SCLC coexisting with Warthin's tumor and parotid small cell carcinoma with lung metastasis, should be differentiated from parotid metastasis of lung cancer with caution For cases presented as SCLC, more aggressive strategies, such as chemotherapy with immunotherapy and maintenance therapy, may be more suitable. Due to the greater tendency of brain metastasis in such diseases, whole-brain radiation therapy, stereotactic radiosurgery or prophylactic cranial irradiation should be applied to corresponding patients in time. Additionally, lung cancer parotid metastases may be a marker of poor prognosis.
据报道,大多数腮腺转移瘤来自头颈部;然而,由肺癌转移而来的病例极为罕见。漏诊和误诊情况屡有发生。因此,准确识别肺癌腮腺转移的临床特征至关重要。然而,目前关于这个问题的研究大多是病例报告,对其详细和系统的方面知之甚少。我们报告了3例肺癌腮腺转移病例,然后通过“PubMed”和“Web of Science”系统检索类似病例。最终,23例患者纳入本研究。其中83%为男性,19例患者年龄超过50岁。在所有提及吸烟史的病例中,93%为吸烟者。主要病理类型为小细胞肺癌(SCLC,13例,56%)。17例合并其他部位转移,其中一半以上为脑转移。生存时间为3个月至17年,对于SCLC患者,仅为3个月至40个月。可以得出结论,性别、年龄、吸烟史、病理类型和转移模式等临床特征可为诊断提供有价值的证据。除头颈部肿瘤外,肺似乎是腮腺转移瘤最常见的原发部位。SCLC合并沃辛瘤以及腮腺小细胞癌合并肺转移这两种情况,应谨慎与肺癌腮腺转移相鉴别。对于表现为SCLC的病例,更积极的策略,如化疗联合免疫治疗和维持治疗,可能更为合适。由于这类疾病脑转移倾向较大,应及时对相应患者应用全脑放疗、立体定向放射外科或预防性颅脑照射。此外,肺癌腮腺转移可能是预后不良的一个标志。